Shandong Xinhua Pharmaceutical Co., Ltd

Hualu Network Group 中文版

Investor Relation

Information transparency and trust in peers

Investor Relation

INTERIM REPORT

Overseas Regulatory Announcement-Announcement on Sacubitril Valsartan Sodium Tablets Having Obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Minoxidil Liniment Having Obtained Drug Registration Certificate

Proposed Amendments to the Articles of Association and Related Rules and Procedures

Announcement Notice of Board Meeting

Overseas Regulatory Announcement-Announcement on Finasteride Tablets of Subsidiary Having Obtained Drug Registration Certificate

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2025

Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information

Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information

Overseas Regulatory Announcement- Announcement on the Completion of Enrollment of the First Patient in China for Phase II Clinical Trials of OAB-14 Dry Suspension

Overseas Regulatory Announcement- Announcement on the Completion of Enrollment of the First Patient in China for Phase II Clinical Trials of OAB-14 Dry Suspension

Overseas Regulatory Announcement-Announcement on Sacubitril Valsartan Sodium Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs

Overseas Regulatory Announcement-Announcement on Sacubitril Valsartan Sodium Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs

Overseas Regulatory Announcement-Announcement on Ivabradine Hydrochloride Tablets Having Obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Ivabradine Hydrochloride Tablets Having Obtained Drug Registration Certificate

总条数: 30条

＜ 1 2 3 ＞

跳转到: 页